INBRAIN Neuroelectronics, a pioneer in graphene-based brain-computer interface therapeutics (BCI-Tx), has announced a strategic collaboration with Microsoft to accelerate the development of next-generation, AI-enabled neurotechnologies. The partnership will leverage Microsoft Azure’s AI and data infrastructure, including time-series large language models (LLMs), to enable INBRAIN’s intelligent neural platform to learn and adapt in real time to individual brain signals.

This agentic AI approach, where AI autonomously acts on real-time data; aims to revolutionize precision neurology, enabling closed-loop treatments for neurological conditions like Parkinson’s disease, epilepsy, and psychiatric disorders.

“Our goal is to build the most intelligent, autonomous, and personalized interface between the nervous system and AI,” said Carolina Aguilar, CEO & Co-Founder of INBRAIN. Microsoft’s Clare Barclay added that the collaboration represents “the next frontier of AI” in healthcare.

Built on graphene’s superior conductivity and biocompatibility, INBRAIN’s neural technology could redefine neurological therapeutics through ethical, data-driven innovation.